ArticleBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2025
A novel composite biomarker score for the identification of cognitive impairment in patients with heart failure: a pilot study.
Article in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundAmong 6.7 million Americans with heart failure (HF), 40%-60% are estimated to have mild cognitive impairment (MCI) and are at-risk for vascular contributions to cognitive impairment and dementia (VCID). This pilot study examined whether neurodegenerative and inflammatory serum biomarkers are elevated in HF and whether a combination of these biomarkers predicts cognitive performance.
methodsThirty-four HF patients (mean age = 69 years, 62% male) were recruited from Banner-University cardiology clinics and underwent blood sampling and neuropsychological testing to derive an 'Actual Composite Cognitive Score.' Age-matched healthy controls included (i) 11 individuals (mean age = 63 years, 20% male) who completed identical procedures and (ii) 24 individuals used exclusively for biomarker analysis. Biomarkers-serum neurofilament light chain (NfL), plasma phosphorylated tau (pTau181, pTau217), placental growth factor (PlGF), cytokines, and NT-proBNP-were quantified using Quanterix Simoa, Milliplex, and Elecsys (Roche) assays.
resultHF participants scored worse in cognitive assessments than controls (
conclusionThese results establish a Composite Biomarker Cognitive Score, which is predictive of cognitive impairment in HF, and may aid in identifying HF patients suitable for cognitive-protective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.